Selinexor

FDA label information for this drug is available at DailyMed.

Use in Cancer

Selinexor is approved to treat:

• Diffuse large B-cell lymphoma (certain types). It is used in adults whose disease has relapsed (come back) or is refractory (does not respond to treatment) and who have received at least two types of systemic therapy.¹
• Multiple myeloma. It is used:
  • With bortezomib and dexamethasone in adults who have received at least one treatment.
  • With dexamethasone in adults whose disease has relapsed or is refractory and who have received at least four treatments that included at least two proteasome inhibitors, at least two immunomodulating agents, and an anti-CD38 monoclonal antibody.

¹This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that selinexor provides a clinical benefit in these patients.

Selinexor is also being studied in the treatment of other types of cancer.

More About Selinexor

Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.

More About Selinexor – A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Selinexor – Check for trials from NCI’s list of cancer clinical trials now accepting patients.